Vigabatrin

The Treatment of Epilepsy: Third Edition

Volumn , Issue , 2009, Pages 699-712

  Krämer, Günter ^a   Wohlrab, Gabriele ^b  

^a SWISS EPILEPSY CENTER   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Infantile spasms (West syndrome); Pharmacokinetics in adults; Teratogenic effects; Vigabatrin; Vigabatrin associated MRI abnomalities in infants; Vigabatrin induced visual field constriction; Vigabatrin irreversible suicide inhibitor of GABA transaminase

Indexed keywords

EID: 84891504318     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444316667.ch56     Document Type: Chapter

References (157)

1. Grant SM, Heel RC. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1991;41:889-926.
2. Ben-Menachem E. Vigabatrin. In: Levy RH, Mattson RH, Meldrum BS, Perucca E (eds). Antiepileptic Drugs, 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2002: 855-863.
3. Gale LK, Iadarola MJ. Seizure protection and increased nerve-terminal GABA: delayed effects of GABA transaminase inhibition. Science 1980;208:288-291.
4. Ben-Menachem E, Dulac O, Chiron C. Vigabatrin. In: Engel J Jr, Pedley TA (eds). Epilepsy: A Comprehensive Textbook, 2nd edn. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, 2008: 1683-1693.
5. Butler WH. The neuropathology of vigabatrin. Epilepsia 1989; 30(Suppl. 3): S15-S17.
6. Cannon DJ, Butler WH, Mumford JP, Lewis PJ. Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. J Child Neurol 1991; 6(Suppl. 2): S17-S24.
7. Patsalos PN, Duncan JS. The pharmacology and pharmacokinetics of vigabatrin. Rev Contemp Pharmacother 1995;6:447-456.
8. Jung MJ, Palfreyman MG. Vigabatrin. Mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS (eds). Antiepileptic Drugs, 4th edn. New York: Lippincott-Raven, 1995: 903-913.
9. Richens A, McEwan JR, Deybach JC, Mumford JP. Evidence for both in vivo and in vitro interaction between vigabatrin and alanine transaminase. Br J Clin Pharmacol 1997;43:163-168.
10. Schechter PJ, Hanke, NFJ, Grove J, et al. Biochemical and clinical effects of γ-vinyl GABA in patients with epilepsy. Neurology 1984;34:182-186.
11. Petroff OAC, Rothman DL, Behar RL, Mattson RH. Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Neurology 1996;46:1459-1463.
12. Petroff OAC, Hyder F, Collins T, et al. Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures. Epilepsia 1999;40:958-964.
13. Haegele KD, Schechter PJ. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the inactive S-enantiomer. Clin Pharmacol Ther 1986;40:581-586.
14. Frisk-Holmberg M, Kerth P, Meyer P. Effect of food on the absorption of vigabatrin. Br J Clin Pharmacol 1889; 27(Suppl): S23-S25.
15. Rey E, Pons G, Olive G. Vigabatrin. Clinical pharmacokinetics. Clin Pharmacokinet 1992;23:267-278.
16. Ben-Menachem E, Persson LI, Schechter PJ, et al. Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy. Epilepsy Res 1988;2:96-101.
17. Tran A, O'Mahoney T, Rey E, et al. Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers. Br J Clin Pharmacol 1998;45:409-411.
18. Browne TR, Mattson TH, Penry JK, et al. Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology 1987;37:184-189.
19. Haegele KD, Huebert ND, Ebel M, Tell GP, Schechter PJ. Pharmacokinetics of vigabatrin: implications of creatinine clearance. Clin Pharmacol Ther 1988;44:558-565.
20. Vauzelle-Kervroëdan F, Rey E, Pons G, et al. Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures. Br J Clin Pharmacol 1996;42:779-781.
21. Rey E, Pons G, Richard MO, et al. Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl-GABA) in epileptic children. Br J Clin Pharmacol 1990;30:253-257.
22. Müller SG, Weber OM, Duc CO, et al. Effects of vigabatrin on brain GABA+/CR signals in patients with epilepsy monitored by 1H-NMRspectroscopy: responder characteristics. Epilepsia 2001;42:29-40.
23. Juhasz C, Muzik O, Chugani DC, et al. Prolonged vigabatrin treatment modifies developmental changes of GABA A-receptor binding in young children with epilepsy. Epilepsia 2001;42:1320-1326.
24. Bachmann D, Ritz R, Wad N, Haefeli E. Vigabatrin dosing during haemodialysis. Seizure 1996;5:239-242.
25. Armijo JA, Arteaga R, Valdizán EM, Herranz JL. Coadministration of vigabatrin and valproate in children with refractory epilepsy. Clin Neuropharmacol 1992;15:459-469.
26. Szylleyko OJ, Hoke JF, Eller MG, et al. A definitive study evaluating the pharmacokinetics of vigabatrin in patients with epilepsy. Epilepsia 1993; 34(Suppl. 6): 41-42.
27. Reidenberg P, Glue P, Banfield CR, et al. Pharmacokinetic interaction studies between felbamate and vigabatrin. Br J Clin Pharmacol 1995;40:157-160.
28. Gatti G, Bartoli A, Marchiselli R. Vigabatrin-induced decrease in phenytoin concentration does not involve a change in phenytoin bioavailability. Br J Clin Pharmacol 1993;36:603-606.
29. Rimmer EM, Richens A. Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol 1989; 27: S27-S33.
30. Dalla Bernardina B, Fontana E, Vigevano F, et al. Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a singleblind dose-increasing study. Epilepsia 1995;36:687-691.
31. Sanchez-Alcaraz A, Quintana MB, Lopez E, et al. Effect of vigabatrin on the pharmacokinetics of carbamazepine. J Clin Pharm Ther 2002;27:427-430.
32. Jedrzejczak J, Dlawichowska E, Owczarek K, Majkowski J. Effect of vigabatrin addition on carbamazepine blood serum levels in patients with epilepsy. Epilepsy Res 2000;39:115-120.
33. Bartoli A, Gatti G, Cipolla G, et al. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. Epilepsia 1997;38:702-707.
34. Arteaga R, Herranz JL, Valdizan, EM, Armilo JA. Gamma-vinyl-GABA (vigabatrin): relationship between dosage, plasma concentrations, platelet GABA-transaminase inhibition, and seizure reduction in children. Epilepsia 1992;33:923-931.
35. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008;49:1239-1276.
36. Vinters HV. Histopathology of brain tissue from patients with infantile spasms. Int Rev Neurobiol 2002;49:63-76.
37. Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameters: medical treatment of infantile spasms. Neurology 2004;62:1668-1681.
38. Appleton RE, Peters ACB, Mumford JP, et al. Randomised, placebocontrolled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999;40:1627-1633.
39. Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia 1997;38:1270-1274.
40. Elterman RD, Shields WD, Mansfield KA, et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001;57:1416-1421.
41. Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomized controlled trail. Lancet 2004;364:1773-1778.
42. Lux AL, Edwards SW, Hancock E, et al. The United Kingdom infantile spasm study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomized trial. Lancet 2005;4:712-717.
43. Aicardi J, Mumford JP, Dumas C, Wood S (Sabril IS Investigator and Peer Review Groups). Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Epilepsia 1996;37:638-642.
44. Wohlrab G, Boltshauser E, Schmitt B. Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome. Neuropediatrics 1998;29:133-136.
45. Covanis A, Theodorou V, Lada C, et al. The first-line use of vigabatrin to achieve complete control of seizures. J Epilepsy 1998;11:265-269.
46. Siemes H, Brandl U, Spohr HL, et al. Long-term follow-up study of vigabatrin in pretreated children with West syndrome. Seizure 1998;7:293-297.
47. Granström ML, Gaily E, Liukkonen E. Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms. Epilepsia 1999;40:950-957.
48. Fejerman N, Cersosimo R, Caraballo R, et al. Vigabatrin as a firstchoice drug in the treatment of West syndrome. J Child Neurol 2000;15:161-165.
49. Kankirawatana P, Raksadawan N, Balangkura K. Vigabatrin therapy in infantile spasms. J Med Assoc Thai 2002; 85(Suppl. 2): S778-S783.
50. Chiron C, Dulac O, Beaumont D, et al. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991; 6(Suppl. 2): S52-S59.
51. Mitchell WG, Shah NS. Vigabatrin (VGB) for infantile spasms: nondose dependent response. Epilepsia 2000;41:187.
52. Tay SKH, Ong HT, Low PS. The use of vigabatrin in infantile spasms in Asian children. Ann Acad Med Singapore 2001;30:26-31.
53. Vanhatalo S, Nousiainen I, Eriksson K, et al. Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia 2002;43:748-756.
54. Capovilla G, Beccaria F, Montagnini A, et al. Short-term nonhormonal and nonsteroid treatment in West syndrome. Epilepsia 2003;44:1058-1088.
55. Kröll-Seger J, Kaminska A, Moutard ML, et al. Severe relapse of epilepsy after vigabatrin withdrawal: for how long should we treat symptomatic infantile spasms. Epilepsia 2007;48:612.
56. Chiron C, Dumas C, Jambaqué I, et al. (1997) Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997;26:389-395.
57. Hancock E, Osborne JP. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol 1999;14:71-74.
58. Jambaqué J, Chiron C, Dumas C, et al. Mental and behavioral outcome of infantile epilepsy treated with vigabatrin in tuberous sclerosis patients. Epilepsy Res 2000;38:151-160.
59. Curatolo P, Verdecchia M, Bombardieri R. Vigabatrin for tuberous sclerosis complex. Brain Dev 2001;23:649-653.
60. Curatolo P, Verdecchia M, Bombardieri R. Tuberous sclerosis complex: a review of neurological aspects. Eur J Paediatr Neurol 2002;6:15-23.
61. Riikonen R. The latest on infantile spasms. Curr Opin Neurol 2005;18:91-95.
62. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion. J Child Neurol 2005; 20: S1-S56.
63. Tassi L, Colombo N, Garbelli R, et al. Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging and surgical outcome. Brain 2002;125:1719-1732.
64. Lortie A, Plouin P, Chiron C, et al. Characteristics of epilepsy in focal cortical dysplasia in infancy. Epilepsy Res 2002;51:133-145.
65. Parisi P, Bombardieri R, Curatolo P. Current role of vigabatrin in infantile spasms. Pediatric Neurol 2007;11:331-336.
66. Nabbout R, Melki I, Gerbaka B, et al. Infantile spasms in Down syndrome: good response to a short course of vigabatrin. Epilepsia 2001;42:1580-1583.
67. Gropman A. Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency. Ann Neurol 2003; 54: S66-S72.
68. Chau V, Karvelas G, Jacob P, et al. Early treatment of Aicardi syndrome with vigabatrin can improve outcome. Neurology 2004;63:1756-1757.
69. Tekgul H, Serdaroglu G, Karapinar B, et al. Vigabatrin caused rapidly progressive deterioration in two cases with early myoclonic encephalopathy associated with nonketotic hypergycinemia. J Child Neurol 2006;21:82-84.
70. Ferrie CD, Panayiotopoulos CP. The clinical efficacy of vigabatrin in adults. Rev Contemp Pharmacother 1995;6:457-468.
71. Mumford JP, Dam M. Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmacol 1989; 27(Suppl. 1): S101-S107.
72. Beran RG, Berkovic SF, Buchanan N, et al. A double-blind, placebocontrolled cross-over study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure 1996;5:259-265.
73. French JA, Mosier M, Walker S, et al. (the Vigabatrin Protocol 024 Investigative Cohort). A double-blind, placebo-controlled study of vigabatrin 3 g/day in patients with uncontrolled complex partial seizures. Neurology 1996;46:54-61.
74. Dean C, Mosier M, Penry K. Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia 1999;40:74-82.
75. Brodie MJ, Mumford JP, 012 Study Group. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. Epilepsy Res 1999;34:199-205.
76. Kälviäinen R, Äikiä M, Saukkonen AM, et al. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol 1995;52:989-996.
77. Tanganelli P, Regesta G. Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study. Epilepsy Res 1996;25:257-262.
78. Chadwick D, for the Vigabatrin European Monotherapy Study Group. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet 1999;354:13-19.
79. Sanofi-Aventis, formerly Hoechst Marion Roussel, data on file, 2008.
80. Browne TR, Mattson RH, Penry JK, et al. Multicenter long-term safety and efficacy study of vigabatrin for refractory complex partial seizures; an update. Neurology 1991;41:363-364.
81. Michelucci, R, Veri L, Passarelli D, et al. Long-term follow-up study of vigabatrin in the treatment of refractory epilepsy. J Epilepsy 1994;7:88-93.
82. Löscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 2006;47:1253-1284.
83. Zahner B, Stefan H, Blankenhorn V, et al. Once-daily versus twice-daily vigabatrin: is there a difference? The results of a double-blind pilot study. Epilepsia 1999;40:311-315.
84. Nabbout RC, Chiron C, Mumford J, et al. Vigabatrin in partial seizures in children. J Child Neurol 1997;12:172-177.
85. Herranz JL, Arteaga R, Farr IN, et al. Dose-response study of vigabatrin in children with refractory epilepsy. J Child Neurol 1991; 6(Suppl. 2): S45-S51.
86. Luna D, Dulac O, Pajot N, Beaumont D. Vigabatrin in the treatment of childhood epilepsies: a single-blind placebo-controlled study. Epilepsia 1989;30:430-437.
87. Uldall P, Alving J, Gram L. Vigabatrin in pediatric epilepsy-an open study. J Child Neurol 1991; 6: S38-S44.
88. Dulac O, Chiron C, Luna C, et al. Vigabatrin in childhood epilepsy. J Child Neurol 1991; 6: S30-S37.
89. Fois A, Buoni S, Di Bartolo RM, et al. Vigabatrin treatment in children. Child Nerv Syst 1994;10:244-248.
90. Uldall P, Alving J, Gram L, Høgenhaven H. Vigabatrin in childhood epilepsy: a 5-year follow-up study. Neuropediatrics 1995;26:253-256.
91. Wong V. Open label trial with vigabatrin in children with intractable epilepsy. Brain Dev 1995;17:249-252.
92. Sheth RD, Buckley D, Penney S, et al. Vigabatrin in childhood epilepsy: comparable efficacy for generalized and partial seizures. Clin Pharmacol 1996;19:297-304.
93. Dimova PS, Korinthenberg R. Efficacy of lamotrigine and vigabatrin in drug-restistant epilepsies of childhood. Pediatr Neurol 1999;21:802-807.
94. Prasad AN, Penney S, Buckley DJ. The role of vigabatrin in childhood seizure disorders: results from a clinical audit. Epilepsia 2001;42:54-61.
95. Chiron C, Dulac O, Gram L. Vigabatrin withdrawal randomized study in children. Epilepsy Res 1996;25:209-215.
96. Sobaniec W, Kulak W, Strzelecka J, et al. A comparative study of vigabatrin vs. carbamazepine in monotherapy in newly diagnosed partial seizures in children. Pharmacological Reports 2005;57:646-653.
97. Zamponi N, Cardinali C. Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. Arch Neurol 1999;56:605-607.
98. Gobbi G, Pini A, Bertani G, et al. Prospective study of first-line vigabatrin monotherapy in childhood partial epilepsies. Epilepsy Res 1999;35:29-37.
99. McDonald DGM, Najam Y, Keegan MB, et al. The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of childhood. Seizure 2005;14:112-116.
100. Kluger G, Berz K, Holthausen H. The long-term use of vigabatrin and lamotrigine in patients with severe childhood onset epilepsy. Eur J Paed Neurol 2001;5:37-40.
101. Livingston JH, Beaumont D, Arzimanoglou A, Aicardi J. Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharmacol 1989; 27(Suppl. 1): 109-112.
102. Lortie A, Chiron C, Dumas C, et al. Optimizing the indication of vigabatrin in children with refractory epilepsy. J Child Neurol 1997;12:253-259.
103. Gherpelli JLD, Guerreiro MM, da Costa JC, et al. Vigabatrin in refractory childhood epilepsy. The Brazilian multicenter study. Epilepsy Res 1997;29:1-6.
104. Turanli G, Celebi A, Yalnizoglu D, et al. Vigabatrin in pediatric patients with refractory epilepsy. Turk J Pediatr 2006;48:25-30.
105. Baxter PS, Gardner-Medwin D, Barwick DD, et al. Vigabatrin monotherapy in resistant neonatal seizures. Seizure 1995;4:57-59.
106. Appleton R, Hughes A, Beirne M, et al. Vigabatrin in the Landau-Kleffner syndrome (letter). Dev Med Child Neurol 1993;35:457-459.
107. Kalra V, Gulati S, Pandey RM, et al. West syndrome and other infantile epileptic encephalopathies-Indian hospital experience. Brain Dev 2002;24:130-139.
108. Lopez-Valdes E, Hernandez-Lain A, Simon R, et al. Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients. Rev Neurol 1996;24:1255-1257.
109. Feucht M, Brantner-Inthaler S. γ-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study. Epilepsia 1994; 35, 993-998.
110. Appleton RE. Vigabatrin in the management of generalized seizures in children. Seizure 1995;4:45-48.
111. Vogt H, Krämer G. Vigabatrin und Lamotrigin. Erfahrungen mit zwei neuen Antiepileptika an der Schweizerischen Epilepsie-Klinik. Schweiz Med Wochenschr 1995;125:125-132.
112. Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev 2000;22:75-80.
113. Yang MT, Lee WT, Chu LW, et al. Anti-epileptic drug-induced de novo absence seizures. Brain Dev 2003;25:51-56.
114. Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsies. Brain 2006;129:1281-1292.
115. Künzle C, Steinlin M, Wohlrab G, et al. Adverse effect of vigabatrin in Angelman syndrome. Epilepsia 1998;39:1213-1215.
116. Fisher RS, Kerrigan JF 3rd. Vigabatrin. Toxicity. In: Levy RH, Mattson RH, Meldrum BS (eds). Antiepileptic Drugs, 4th edn. New York: Lippincott-Raven, 1995: 931-939.
117. Sälke-Kellermann A, Baier H, Rambeck B, et al. Acute encephalopathy with vigabatrin. Lancet 1993;342:185.
118. Sharif MK, Sander JWA, Shorvon SD. Acute encephalopathy with vigabatrin. Lancet 1993;342:619.
119. Haas-Lude K, Wolff M, Riethmüller J, et al. Acute encephalopathy associated with vigabatrin in a six-month-old girl. Epilepsia 2000;41:628-630.
120. Sander JWAS, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatr 1991;54:435-439.
121. Thomas L, Trimble M, Schmitz B, Ring H. Vigabatrin and behaviour disorders: a retrospective survey. Epilepsy Res 1996;25:21-27.
122. Aldenkamp AP, Vermeulen J, Mulder OG, et al. γ-vinyl GABA (vigabatrin) and mood disturbances. Epilepsia 1994;35:999-1004.
123. Levinson DF, Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology 1999;53:1503-1511.
124. Dodrill CB, Arnett JL, Sommerville KW, Sussman NM. Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia 1995;36:164-173.
125. Vallat C, Rivier F, Bellet H, et al. Treatment with vigabatrin may mimic γ-aminoadipic aciduria. Epilepsia 1996;37:803-805.
126. Preece MA, Sewell IJ, Taylor JA, Green A. Vigabatrin-interference with urinary amino acid analysis. Clin Chim Acta 1993;218:113-116.
127. Eke T, Talbot JF, Lawdon MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997;314:180-181.
128. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction. Electroretinogram and ophthalmologic findings. Neurology 1998;50:614-618.
129. Kalviäinen R, Nousiainen I, Mäntyjärvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999;53:922-926.
130. Kalviainen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 2001;15:217-230.
131. Wohlrab GC, Boltshauser E, Schmitt B, et al. Visual field constriction is not limited to children treated with vigabatrin. Neuropediatrics 1999;30:130-132.
132. Gross-Tsur V, Banin E, Shahar E, et al. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol 2000;48:60-64.
133. Iannetti P, Spalice A, Perla FM, et al. Visual field constriction in children with epilepsy on vigabatrin treatment. Pediatrics 2000;106:838-842.
134. Russell-Eggitt IM, Mackey DA, Taylor DSI, et al. Vigabatrin-associated visual field defects in children. Eye 2000;14:334-339.
135. You SJ, Ahn HS, Ko TS. Vigabatrin and visual field defects in pediatric epilepsy patients. J Korean Med Sci 2006;21:728-732.
136. Wild JM, Ahn HS, Baulac M, et al. Vigabatrin and epilepsy: lessons learned. Epilepsia 2007;48:1318-1327.
137. Best JL, Acheson JF. The natural history of vigabatrin associated visual field defects in patients electing to continue their medication. Eye 2005;19:41-44.
138. Kinirons P, Cavalleri GL, O'Rourke D, Doherty CP, Reid I, Logan P, et al. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia 2006;47:311-317.
139. Kinirons P, Cavalleri GL, Singh R, et al. A pharmacogenetic exploration of vigabatrin-induced visual field constriction. Epilepsy Res 2006;70:144-152.
140. Malmgren K, Ben-Menachem E, Frisén L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 2001;42:609-615.
141. Conway M, Cubbidge RP, Hosking SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 2008;49:108-116.
142. Versino M, Veggiotti P. Reversibility of vigabatrin-induced visual-field defect. Lancet 1999;354:486.
143. Giordano L, Valserati D, Vignoli A, et al. Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favourable factor? Neurol Sci 2000; 21: 185-186.
144. Buncic JR, Westall CA, Panton CM, et al. Characteristic retinal atrophy with secondary 'inverse' optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 2004;111:1935-1942.
145. Westall CA, Nobile R, Morong S, et al. Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Documenta Ophthalmologica 2003;107:299-309.
146. Spencer EL, Harding GFA. Examining visual field defects in the pediatric population exposed to vigabatrin. Documenta Ophthalmologica 2003;107:281-287.
147. Parisi P, Tommasini P, Piazza G, et al. Scotopic threshold response changes after vigabatrin therapy in a child without visual field defects: a new electroretinographic marker of early damage? Neurobiol Dis 2004; 15: 573-579.
148. Desguerre I, Marti I, Valayannopoulos V, et al. Transient magnetic resonance diffusion abnormalities in West syndrome: the radiological expression of non-convulsive status epilepticus? Dev Med Child Neuro 2008; 50: 112-116.
149. Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 2009;50:195-205.
150. Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 2009;50:184-194.
151. Milh M, Villeneuve N, Chapon F, et al. Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin. J Child Neurol 2009;24:305-315.
152. Kim SS, Chang K-H, Kim ST, et al. Focal lesion of the splenium of the corpus callosum in epileptic patients: antiepileptic drug toxicity? Am J Neuroradiol 1999; 20: 125-129.
153. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia 1996; 37(Suppl. 6): S34-S44.
154. Sorri I, Herrgard E, Viinikainen K, et al. Ophthalmologic and neurological findings in two children exposed to vigabatrin in utero. Epilepsy Res 2005;65:646-653.
155. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs, I: treatment of new-onset epilepsy: report of the TTA and QSS Subcommitees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004;45:401-409.
156. French JA, Kanner AM, Bautista J, et al. (2004) Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy: report of the TTA and QSS Subcommitees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004;45:410-423.
157. Vigabatrin Paediatric Advisory Group. Guidelines for prescribing vigabatrin in children has been revised. Br Med J 2000;320:1404-1405.